Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients

M. Svoboda, J. Sana, M. Redova, J. Navratil, M. Palacova, P. Fabian, O. Slaby, R. Vyzula,

. 2012 ; 7 () : 31.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12034640

Grantová podpora
NS10357 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast cancer, characterized by higher incidence in young women and a very poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs playing significant role in the pathogenesis of many cancers including breast cancer. Therefore, miRNAs are also potential prognostic and/or predictive biomarkers in triple-negative breast cancer patients. METHODS: Thirty-nine TNBC patients with available formalin-fixed paraffin-embedded (FFPE) tissues were enrolled in the study. MiR-34a, miR-34b, and miR-34c were analyzed using qRT-PCR and correlated to clinico-pathological features of TNBC patients. RESULTS: Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients. No other significant associations between miR-34a, miR-34b, and miR-34c with available clinical pathological data were observed. CONCLUSIONS: MiR-34b expression negatively correlates with disease free survival and overall survival in TNBC patients. Thus, miR-34b may present a new promising prognostic biomarker in TNBC patients, but independent validations are necessary.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034640
003      
CZ-PrNML
005      
20240903092956.0
007      
ta
008      
121023s2012 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/1746-1596-7-31 $2 doi
035    __
$a (PubMed)22439831
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, the Czech Republic. msvoboda@mou.cz
245    10
$a MiR-34b is associated with clinical outcome in triple-negative breast cancer patients / $c M. Svoboda, J. Sana, M. Redova, J. Navratil, M. Palacova, P. Fabian, O. Slaby, R. Vyzula,
520    9_
$a BACKGROUND: Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast cancer, characterized by higher incidence in young women and a very poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs playing significant role in the pathogenesis of many cancers including breast cancer. Therefore, miRNAs are also potential prognostic and/or predictive biomarkers in triple-negative breast cancer patients. METHODS: Thirty-nine TNBC patients with available formalin-fixed paraffin-embedded (FFPE) tissues were enrolled in the study. MiR-34a, miR-34b, and miR-34c were analyzed using qRT-PCR and correlated to clinico-pathological features of TNBC patients. RESULTS: Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients. No other significant associations between miR-34a, miR-34b, and miR-34c with available clinical pathological data were observed. CONCLUSIONS: MiR-34b expression negatively correlates with disease free survival and overall survival in TNBC patients. Thus, miR-34b may present a new promising prognostic biomarker in TNBC patients, but independent validations are necessary.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádory prsu $x genetika $x mortalita $x patologie $7 D001943
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mikro RNA $x analýza $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a receptor erbB-2 $x biosyntéza $x genetika $7 D018719
650    _2
$a receptory pro estrogeny $x biosyntéza $x genetika $7 D011960
650    _2
$a receptory progesteronu $x biosyntéza $x genetika $7 D011980
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a nádorové biomarkery $x genetika $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sana, Jiri
700    1_
$a Lojová, Martina, $d 1983- $7 mub2011663118
700    1_
$a Navrátil, Jiří $7 xx0164164
700    1_
$a Palacova, Marketa
700    1_
$a Fabian, Pavel
700    1_
$a Slaby, Ondrej
700    1_
$a Vyzula, Rostislav
773    0_
$w MED00165474 $t Diagnostic pathology $x 1746-1596 $g Roč. 7 (2012), s. 31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22439831 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20121023 $b ABA008
991    __
$a 20240903092953 $b ABA008
999    __
$a ok $b bmc $g 956650 $s 792137
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 7 $d 31 $i 1746-1596 $m Diagnostic pathology $n Diagn Pathol $x MED00165474
GRA    __
$a NS10357 $p MZ0
LZP    __
$a Pubmed-20121023

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...